The Oppenheimer Holdings, Inc. Reiterates “Buy” Rating for Integra LifeSciences Holdings Corporation (IART)

The Oppenheimer Holdings, Inc. Reiterates “Buy” Rating for Integra LifeSciences Holdings Corporation (IART)

Integra LifeSciences Holdings Corporation (NASDAQ:IART)‘s stock had its “buy” rating reaffirmed by equities research analysts at Oppenheimer Holdings, Inc. in a report released on Thursday.

Several other research firms also recently issued reports on IART. Zacks Investment Research upgraded Integra LifeSciences Holdings Corporation from a “hold” rating to a “buy” rating and set a $57.00 price target for the company in a research note on Tuesday, October 3rd. Barclays PLC restated an “equal weight” rating and set a $53.00 target price (up previously from $47.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Tuesday, September 12th. Jefferies Group LLC restated a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research note on Sunday, September 10th. Cantor Fitzgerald assumed coverage on Integra LifeSciences Holdings Corporation in a research note on Thursday, June 29th. They set an “overweight” rating and a $65.00 target price for the company. Finally, BidaskClub downgraded Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Five equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $54.27.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded down 6.01% during trading on Thursday, reaching $47.88. The company had a trading volume of 1,702,713 shares. The company has a market capitalization of $3.74 billion, a P/E ratio of 58.39 and a beta of 0.71. Integra LifeSciences Holdings Corporation has a 12 month low of $37.71 and a 12 month high of $56.42. The stock has a 50 day moving average of $50.64 and a 200-day moving average of $49.97.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last released its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.02). The company had revenue of $278.83 million for the quarter, compared to the consensus estimate of $286.00 million. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The business’s revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.93 EPS. Equities research analysts expect that Integra LifeSciences Holdings Corporation will post $1.91 EPS for the current fiscal year.

In other news, Director Donald E. Morel, Jr. purchased 2,500 shares of the business’s stock in a transaction on Thursday, August 3rd. The stock was purchased at an average price of $49.29 per share, with a total value of $123,225.00. Following the acquisition, the director now directly owns 29,612 shares in the company, valued at approximately $1,459,575.48. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Donald E. Morel, Jr. purchased 10,000 shares of the business’s stock in a transaction on Friday, August 4th. The stock was purchased at an average cost of $49.25 per share, with a total value of $492,500.00. Following the acquisition, the director now owns 29,612 shares in the company, valued at $1,458,391. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 17,550 shares of company stock valued at $864,842. Insiders own 21.50% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Eagle Asset Management Inc. raised its holdings in Integra LifeSciences Holdings Corporation by 39.0% in the 2nd quarter. Eagle Asset Management Inc. now owns 1,647,018 shares of the life sciences company’s stock valued at $89,778,000 after acquiring an additional 461,977 shares in the last quarter. Strs Ohio raised its holdings in shares of Integra LifeSciences Holdings Corporation by 60.4% in the 2nd quarter. Strs Ohio now owns 7,700 shares of the life sciences company’s stock worth $419,000 after buying an additional 2,900 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of Integra LifeSciences Holdings Corporation by 116.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 244,982 shares of the life sciences company’s stock worth $10,322,000 after buying an additional 131,995 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Integra LifeSciences Holdings Corporation by 12.3% in the 2nd quarter. Jennison Associates LLC now owns 697,772 shares of the life sciences company’s stock worth $38,036,000 after buying an additional 76,548 shares in the last quarter. Finally, State of Alaska Department of Revenue raised its holdings in shares of Integra LifeSciences Holdings Corporation by 80.1% in the 2nd quarter. State of Alaska Department of Revenue now owns 11,939 shares of the life sciences company’s stock worth $650,000 after buying an additional 5,309 shares in the last quarter. 84.90% of the stock is owned by hedge funds and other institutional investors.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Related posts

Leave a Comment